Akcea Therapeutics, Inc.
|Number of Estimates|
Akcea Therapeutics, Inc. engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
Market Cap: 1.83 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 93.9 Million
Float: 15.5 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 353 trading days
From: 2018-08-07 To: 2019-12-12
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|